Pfizer PFE

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Johnson & Johnson Is The Most Attractive Mega-Cap Pharma Stock For Income Investors

      Headlines

      Tue, 30 Sep 2014

      stocks that match the above criteria are as follows: Johnson & Johnson (NYSE: JNJ ) Novartis AG (NYSE: NVS ) Pfizer (NYSE: PFE ) Merck & Co. (NYSE: MRK ) Johnson & Johnson is the most diversified company in this group as its pharmaceutical

    2. Update: AstraZeneca Moves Closer To EU Approval For Moventig

      Headlines

      Tue, 30 Sep 2014

      well as its attractive buyout prospects in light of Pfizer 's (NYSE: PFE ) recent attempts to court Astra (which ultimately ..... support my claim that Astra can flourish independent of Pfizer . Thus, I reaffirm my bull thesis since I'm confident

    3. Can Pfizer Grow Without A Big Acquisition?

      Headlines

      Mon, 29 Sep 2014

      peers with aging drug pipelines, Pfizer (NYSE: PFE ) has been aggressively acquiring ..... investors need to evaluate whether Pfizer can grow without a big acquisition ..... is likely off the table now for Pfizer after the initial $118 Complete

    4. Pfizer drug effective in patients with rare lung cancer -study

      Headlines

      Sat, 27 Sep 2014

      Sept 27 (Reuters) - Pfizer Inc's Xalkori, which treats lung cancer patients with a specific gene mutation, proved effective in shrinking tumors in those with an even rarer form of the disease, according to data presented at a medical meeting on Saturday.

    5. Fitch Affirms Pfizer's IDR at 'A+'; Outlook Stable

      Headlines

      Fri, 26 Sep 2014

      September 26 (Fitch) Fitch Ratings has affirmed Pfizer Inc.'s ( Pfizer 's) ratings, including the 'A+' Issuer Default ..... release. KEY RATING DRIVERS --Fitch forecasts that Pfizer will operate with total debt leverage rangi

    6. Can Valeant's Glaucoma Drug Peak Sales Be Much Lower Than Claimed?

      Headlines

      Fri, 26 Sep 2014

      drugs are old and well-established with no revenue growth. For instance the most widely prescribed drug is Pfizer 's (NYSE: PFE ) latanoprost (Xalatan) . Xalatan went generic in 2011 and Mylan (NASDAQ: MYL ) is already selling a generic

    7. Pfizer delays start of rivipansel Phase 3, GLYC shares drop

      Headlines

      Fri, 26 Sep 2014

      are under pressure in response to Pfizer 's ( PFE -1.2% ) notification that it ..... impacting formulated drug supply. Pfizer says that it will advise GLYC on ..... exclusive license agreement with Pfizer was signed in October 2011. The

    8. Why Is Merck Running To 52-Week Highs Again? ESMO Conference This Weekend

      Headlines

      Thu, 25 Sep 2014

      no secret, Merck (NYSE: MRK ) has had a great 2014, running up over 20% YTD and outperforming its key rivals Pfizer (NYSE: PFE ), Johnson & Johnson (NYSE: JNJ ), GlaxoSmithKline (NYSE: GSK ), Novartis (NYSE: NVS ), & Bristol-Myers

    9. Thermo Fisher to develop companion diagnostics for GSK and PFE

      Headlines

      Thu, 25 Sep 2014

      Thermo Fisher Scientific (NYSE: TMO ) enters into an agreement with GlaxoSmithKline (NYSE: GSK ) and Pfizer (NYSE: PFE ) to develop a universal next-generation sequencing (NGS) oncology test for solid tumors that will serve as

    10. Hold on there, Allergan

      Headlines

      Wed, 24 Sep 2014

      Pharmaceuticals ( SLXP -0.2% ) which would submarine Allergan's ( AGN +3.7% ) reported acquisition plans as a tactic to thwart Valeant ( VRX +6.9% ). Actavis itself is supposedly a takeover target of Pfizer ( PFE +1% ). Post your comment!

    « Prev12345Next »
    Content Partners